Accendra Health (ACH) Q3 2026 earnings review
Accendra Health cuts its profit outlook as sales shrink
Accendra Health, which delivers medical supplies to patients at home, saw its revenue and operating profit fall again as a promised second-half recovery failed to materialise. Third-quarter revenue dropped 14% from a year ago, and sales outside a lost insurance contract shrank by about 1% by our math after growing in the first half. Incoming chief executive Kenny Gardner-Smith said results fell short of expectations and cut the full-year operating profit outlook by up to 30%, which by our math leaves fourth-quarter profit down more than 40% from a year ago.
| Sales excluding lost insurer contract | -1.2% from a year ago by our math (+2% in Q2) |
|---|---|
| Net revenue | $601.8M -13.7% from a year ago |
| Adjusted Ebitda (operating profit before one-offs) | $47.8M -48.2% from a year ago |
| Full-year Adjusted Ebitda outlook | Cut up to 30% floor of ~$217M vs $310M prior middle of range |
⚖️ Verdict: 🔴🔴 Very Bearish
The story got worse because both pillars of the second-half turnaround broke at once: underlying sales in sleep and wound care shrank, and higher supplier prices plus uncollected bills crushed margins. Cutting the full-year profit target to as low as $217 million against $1.7 billion of net debt removes any cash cushion before December's bond interest payment. One bright spot: selling a non-core business for $33 million rebuilt cash to $27 million.
The question now is whether Accendra can pay its December bond interest and fund patient equipment without running into debt limits or issuing stock. Either the new chief executive's turnaround plan stabilises cash collections and supplier costs quickly, or the company will have to lean harder on its credit line and dilute shareholders. Fourth-quarter cash flow and the upcoming turnaround details will settle it.
🐂 Bull Case
Asset Sale and Refunds Rebuilt Cash Balances
Accendra Health, which delivers medical supplies for diabetes and sleep apnea to patients at home, ended June with just $7.7 million in cash. In the third quarter, the company sold a non-core business for $32.5 million in cash and recorded a $32.5 million gain. That sale, along with $35 million of net borrowing on its credit line, lifted ending cash to $26.6 million.
What to watch: the fourth-quarter cash balance after December interest payments. Holding cash above $20 million without exhausting the credit line would show that immediate funding pressure has eased.
Lower Equipment Spending Kept Free Cash Positive
Accendra defines free cash flow as operating profit before depreciation and one-offs, minus purchases of medical equipment for patients and cash interest paid. After burning $27.1 million in the first half of 2026, the home-care provider generated $5.8 million of positive free cash flow in the third quarter.
Two timing shifts made that possible. First, spending on patient equipment dropped to $38.5 million, or 6.4% of sales, down from $43.8 million last quarter because the company finished paying for gear tied to a lost insurer contract. Second, cash interest paid was only $10.9 million because interest on its new bonds is paid twice a year.
What to watch: fourth-quarter free cash flow when the first semi-annual bond interest payment comes due. Positive cash generation in the fourth quarter would prove the business can cover its full interest bill from operations.
🐻 Bear Case
Second-Half Profit Recovery Failed to Happen
Three months ago, management lowered its full-year outlook for Adjusted EBITDA (operating profit before depreciation, amortisation and one-off items) to a midpoint of $310 million, which still required second-half profit to rise by more than half over the first six months. Instead, third-quarter Adjusted EBITDA fell 20.5% from the second quarter to $47.8 million, down 48.2% from a year ago.
New chief executive Kenny Gardner-Smith said "our results to date in 2026 have fallen well short of our expectations and potential" and cut the full-year profit target again, to "as much as 30% lower than the $310 million midpoint of the prior outlook range". By our math, that floor is $217 million for the year and implies about $50.8 million in the fourth quarter, meaning the promised second-half rebound is gone.
What to watch: fourth-quarter Adjusted EBITDA against that $50.8 million implied floor. A result below $50 million would mean operating profit is still shrinking entering 2027.
Sales Shrank Even Outside the Lost Insurer
Accendra lost a large commercial insurance contract at the start of 2026, which took $88 million out of third-quarter revenue compared with a year ago. Management previously pointed to modest growth in the rest of its business as proof of healthy demand, and the company's presentation still highlights "favorable end markets" across its medical supply categories.
- Sales excluding the lost insurer: down 1.2% from a year ago by our math, after rising 2% in Q2
- Sleep supplies and equipment: down $6 million from a year ago
- Wound care and home respiratory: down $6 million and $5 million
- Diabetes supplies: up $6 million, the only growing product line
Those category declines cut against the company's claim of healthy end markets, because sales outside the lost contract turned negative even before the full-year outlook implied a 14.4% total revenue drop in the fourth quarter. What to watch: fourth-quarter revenue in sleep and respiratory care. Another decline would show that patient volume losses are spreading beyond the one lost insurer.
Supplier Costs and Uncollected Bills Cut Profit
Gross margin — the share of sales left after paying for medical supplies — fell 2.8 percentage points from a year ago to 43.4%, as cost of net revenue rose to 56.6% of sales. Even after stripping out the $20 million net profit hit from the lost insurance contract, Adjusted EBITDA still fell 33.8% from a year ago by our math.
The company's presentation shows why cost cuts failed to protect margins. Higher prices from equipment manufacturers took $13 million off third-quarter Adjusted EBITDA, general inflation cost another $6 million, and lower cash collection rates on patient bills reduced both revenue and profit by $6 million. Uncollected bills have now hurt profit for three straight quarters.
What to watch: the collection-rate deduction and manufacturer cost drag on the fourth-quarter profit bridge. A smaller deduction would show that billing audits are finally clearing.
Debt Costs and Separation Bills Strained Liquidity
Accendra carries $1.73 billion in net debt, which is nearly eight times its lowered full-year Adjusted EBITDA floor of $217 million by our math. Net interest expense jumped 29.6% from a year ago to $37.6 million in the third quarter following June's debt refinancing, while free cash flow for the first nine months remained negative at $21.3 million.
Cash was also drained by the December 2025 sale of its Products & Healthcare Services unit: Accendra recorded $30 million of reimbursable separation costs in the third quarter, hitting its $65 million cap for the year. The release also added a risk warning about "our ability to cure noncompliance with the New York Stock Exchange listing standards".
What to watch: net debt and credit-line borrowings at year-end. Any further borrowing to pay December bond interest would tighten liquidity heading into 2027.
👓 Other Themes
New Chief Executive Plans Another Turnaround
Kenny Gardner-Smith took over as president and chief executive following Edward Pesicka's retirement announcement last quarter. Gardner-Smith said he has identified four areas to fix the business and that "over the next several months, we will have our value creation plan fully underway", with details to be shared in the coming months. The release gave no savings targets or restructuring costs for the new plan.
💲 Other KPIs
Overhead and administrative spending fell 6.2% from a year ago as Accendra removed costs after losing a major insurer contract. However, because revenue dropped faster, these expenses rose to 41.5% of revenue, up 3.3 percentage points from 38.1% a year ago and up from 39.7% in the second quarter.
Unpaid customer bills on the balance sheet sits 11.9% higher than at the end of 2025 ($95.9 million), even though third-quarter sales are down 15.1% since the fourth quarter of 2025. Working capital cash flows show $12.8 million of cash collected from receivables during the third quarter, easing some of the first-half buildup.
Medical supplies held in stock rose 10.3% from $74.4 million at the end of 2025 and increased from $73.3 million in the second quarter. Building that inventory used $11.1 million of operating cash in the third quarter, ahead of management's previously stated plan to outsource warehouse management late this year.
🔮 Guidance
Cut. Accendra now expects full-year sales "at the bottom end of the prior outlook range" of $2.45 billion to $2.55 billion, down 11.3% from 2025 by our math. That leaves about $607 million of revenue for the fourth quarter, or a 14.4% drop from a year ago. It is the second reduction since the year began at a $2.60 billion midpoint: -$100M in Q2, and -$50M to the floor in Q3.
Cut. Management warned full-year Adjusted EBITDA could be "as much as 30% lower than the $310 million midpoint of the prior outlook range", which puts the floor at $217 million, down 42.1% from 2025 by our math. With $166.2 million earned in the first nine months, that floor implies $50.8 million in the fourth quarter, down 43.6% from a year ago. Second straight cut: -$35M in Q2, and up to -$93M in Q3.
❓ Key Questions
Did Accendra abandon its full-year free cash flow target?
Last quarter management guided for full-year free cash flow to be breakeven to slightly positive, which required generating at least $27.1 million in the second half. The third-quarter release dropped any mention of full-year free cash flow while cutting the profit outlook by up to $93 million.
What are the financial covenant limits after the profit cut?
With full-year Adjusted EBITDA now projected as low as $217 million against $1.73 billion of net debt, net leverage approaches eight times by our math. Management has not disclosed the maximum leverage or minimum interest-coverage ratios required under its credit line and term loan.
Why did sleep and respiratory sales fall excluding the lost insurer?
Management previously expected its nationwide Sleep Center of Excellence rollout to lift sales in the second half of 2026. Instead, excluding the terminated insurer contract, sleep revenue fell $6 million and respiratory fell $5 million from a year ago.
How will Accendra cure its New York Stock Exchange listing warning?
The release's Safe Harbor statement added a reference to curing noncompliance with New York Stock Exchange listing standards, and the balance sheet shows a $568.2 million stockholders' deficit. Investors need to know the deadline and whether a reverse stock split is planned.